St Jude's New C7-XR OCT Intravascular Imaging System

St. Jude Medical to Showcase New Lesion Assessment Technology at TCT 2010

St. Jude Medical, a global medical device company, will highlight recently launched technology, including its new Optical Coherence Tomography (OCT) product platform, at the 22^nd annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, D.C. The new C7-XR(TM) OCT Intravascular Imaging System complements the company's PressureWire(TM) Fractional Flow Reserve (FFR) measurement technology platform, offering physicians a new diagnostic standard for comprehensive intravascular lesion assessment.

The C7-XR OCT Intravascular Imaging System is a leading imaging technology platform that aids physicians in the diagnosis and treatment of cardiovascular disease. The C7-XR System uses near-infrared light to create high-resolution images that allow physicians to visualize and measure important vessel characteristics otherwise invisible or difficult to assess with older imaging technology. The St. Jude Medical OCT product platform expands the company's lesion assessment portfolio, which includes the recently launched PressureWire(TM) Aeris FFR Measurement System, and adds anatomical knowledge to the physiological information provided by FFR measurements. While FFR accurately identifies which lesions to stent, OCT-guided treatment can be especially important for the assessment of stent placement because it shows precisely how the stent is positioned against the artery wall.

St. Jude Medical is the first to offer both OCT and FFR technologies .

In addition to guiding stent selection, the C7-XR System provides physicians with post-stenting information by evaluating the position and deployment of the stent. At follow-up, the OCT technology provides detailed information regarding the inner lining of the vessel and whether there is a reoccurrence of the blood vessel narrowing.